An Implementation Tool For US Professionals: First Void Urine Self-Sampling for Primary HPV Cervical Cancer Screening
The national coverage of cervical cancer screening in the US is falling, with about 1 in 4 women not up to date with screening1. Under-screened women bear the greatest burden of disease. Evidence shows 60-64% of American women diagnosed with cervical cancer were unscreened, highlighting the need to explore alternative methods to improve access2-4. In Read More >
Comparing the costs and diagnostic outcomes of using DNA methylation testing instead of liquid-based cytology within HPV primary cervical cancer screening in the Netherlands.
Publication of our economic evaluation comparing two cervical screening strategies in Belgium: HPV primary versus co-testing
Piss in a pot and pop it in the post: An economic evaluation of vaginal swab and urine self-sampling for HPV primary cervical cancer screening compared with clinician-collected sampling
A cost effectiveness analysis of repeat screening for syphilis in pregnancy as an alternative screening strategy in the UK
Examining the acceptability of offering STI screening in higher educational settings
Cost analysis of near patient chlamydia and gonorrhoea screening and treatment in further education/technical colleges
Cluster-randomised feasibility trial of a chlamydia test and treat (TnT) service in further education colleges
How to prevent cervical cancer: HPV – we are coming to get you!
Cervical screening and HPV testing: Opportunities for rapid tests
We explored the use of a rapid, on-demand human papillomavirus (HPV) test. Interviews with UK experts revealed that a co-located, on-demand HPV test following cytology could reduce the time to cervical screening results by up to a week, with a near-patient primary HPV test followed by cytology triage could radically change the testing paradigm. A follow-up tool we built in Excel was used to understand cervical screening burden and HPV testing across Europe.